GLYC Stock Overview
A biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
GlycoMimetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.24 |
| 52 Week High | US$3.53 |
| 52 Week Low | US$0.14 |
| Beta | 1.78 |
| 1 Month Change | -23.61% |
| 3 Month Change | 51.72% |
| 1 Year Change | -90.40% |
| 3 Year Change | -83.42% |
| 5 Year Change | -95.43% |
| Change since IPO | -97.31% |
Recent News & Updates
Recent updates
We're A Little Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Rate
Jun 27
GlycoMimetics Can Become A Game Changer In Blood Cancers
Mar 21Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Mar 20GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real
Jan 30Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Nov 19Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?
Jan 30Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely
Oct 06GlycoMimetics has a new Chief Medical Officer
Sep 06GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K
Aug 03GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely
Jun 04GlycoMimetics Positive Data For AML Therapy Increasingly Likely
Mar 16Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Nov 20We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully
Aug 20GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study
May 26Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year
May 12GlycoMimetics EPS beats by $0.04
May 03Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Mar 26GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares
Feb 19GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings
Jan 24How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?
Dec 28New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease
Dec 07Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Dec 07The Investment Case For GlycoMimetics
Nov 17Shareholder Returns
| GLYC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.8% | -3.3% | -2.2% |
| 1Y | -90.4% | -1.9% | 23.9% |
Return vs Industry: GLYC underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: GLYC underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| GLYC volatility | |
|---|---|
| GLYC Average Weekly Movement | 55.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GLYC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GLYC's weekly volatility has increased from 32% to 55% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 35 | Harout Semerjian | www.glycomimetics.com |
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein.
GlycoMimetics, Inc. Fundamentals Summary
| GLYC fundamental statistics | |
|---|---|
| Market cap | US$15.61m |
| Earnings (TTM) | -US$39.74m |
| Revenue (TTM) | US$10.00k |
1,561x
P/S Ratio-0.4x
P/E RatioIs GLYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLYC income statement (TTM) | |
|---|---|
| Revenue | US$10.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$10.00k |
| Other Expenses | US$39.75m |
| Earnings | -US$39.74m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.62 |
| Gross Margin | 100.00% |
| Net Profit Margin | -397,350.46% |
| Debt/Equity Ratio | 0% |
How did GLYC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 00:55 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GlycoMimetics, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Huang | Barclays |
| John Newman | Canaccord Genuity |
| Naureen Quibria | Capital One Securities, Inc. |